10.1371/journal.pone.0150602.g008 Martilias S. Farrell Martilias S. Farrell John D. McCorvy John D. McCorvy Xi-Ping Huang Xi-Ping Huang Daniel J. Urban Daniel J. Urban Kate L. White Kate L. White Patrick M. Giguere Patrick M. Giguere Allison K. Doak Allison K. Doak Alison I. Bernstein Alison I. Bernstein Kristen A. Stout Kristen A. Stout Su Mi Park Su Mi Park Ramona M. Rodriguiz Ramona M. Rodriguiz Bradley W. Gray Bradley W. Gray William S. Hyatt William S. Hyatt Andrew P. Norwood Andrew P. Norwood Kevin A. Webster Kevin A. Webster Brenda M. Gannon Brenda M. Gannon Gary W. Miller Gary W. Miller Joseph H. Porter Joseph H. Porter Brian K. Shoichet Brian K. Shoichet William E. Fantegrossi William E. Fantegrossi William C. Wetsel William C. Wetsel Bryan L. Roth Bryan L. Roth Locomotor studies of nuciferine. Public Library of Science 2016 D 4 receptors drug discrimination paradigms.ResultsNuciferine shares 2A 2B 2C PCP HT discriminative stimulus effects antipsychotic drug action nuciferine agonist clozapine discriminative stimulus 1A Nelumbo nucifera Alkaloid Nuciferine RationaleThe similarity ensemble approach profile Psychoactive Drug Screening Program 2016-03-10 09:18:08 Figure https://plos.figshare.com/articles/figure/Locomotor_studies_of_nuciferine_/3108409 <p>(a) Nuciferine suppresses the PCP-induced hyperlocomotor response. Data are presented as total distance travelled in 5-minute bins (left) and as cumulative distance travelled between minute 45 and minute 60 (right). N = 18 mice; ^p<0.05, compared to PCP group. (b) Nuciferine (3.0 mg/kg, 15 minute pretreatment) enhances the hyperlocomotor effect of amphetamine (3.0 mg/kg) administration. N = 14 mice; * < 0.001 compared to Amphetamine group. Data are presented as above.</p>